These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 30635223)
1. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223 [TBL] [Abstract][Full Text] [Related]
2. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Vardakas KZ; Falagas ME Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
4. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108 [TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560 [TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study. Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197 [TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Zavascki AP; Nation RL Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859 [TBL] [Abstract][Full Text] [Related]
8. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin. Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510 [TBL] [Abstract][Full Text] [Related]
10. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS). Truong CB; Durham SH; Qian J Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405 [No Abstract] [Full Text] [Related]
11. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins. Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812 [TBL] [Abstract][Full Text] [Related]
12. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187 [TBL] [Abstract][Full Text] [Related]
13. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221 [TBL] [Abstract][Full Text] [Related]
14. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846 [TBL] [Abstract][Full Text] [Related]
15. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. Pike M; Saltiel E J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156 [TBL] [Abstract][Full Text] [Related]
16. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria. Tuon FF; Rocha JL; Gasparetto J J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325 [TBL] [Abstract][Full Text] [Related]
17. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000 [TBL] [Abstract][Full Text] [Related]
18. Colistin and polymyxin B in critical care. Michalopoulos A; Falagas ME Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952 [TBL] [Abstract][Full Text] [Related]
19. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Aggarwal R; Dewan A Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis. Wang J; Niu H; Wang R; Cai Y Int J Antimicrob Agents; 2019 Apr; 53(4):383-400. PubMed ID: 30447379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]